All posts by U.S. Stem Cell, Inc

USRM Posts Profitable Results for Second Quarter 2018

SUNRISE, FL – August 8, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced results for its second quarter in 2018 — the 10th consecutive quarter where revenue has increased.

For the quarter ending June 30, 2018, the Company posted a revenue increase of 31% to $1.82m, up from $1.39m for the second quarter of last year.  Revenue also increased for the six months ended June 30, 2018, to $3.53m, up 39% from $2.54m for the same period last year.

Profit margin for the second quarter also increased, to 69% from 67% for the same period last year, and profit margin for the first six months of this year increased to 70% from 68% in the first six months of 2017.  Gross profit was also up for both periods, with a 34% increase to $1.25m from $934k for the second quarter, and a 43% increase to $2.46m from $1.73m for the six-month period.

For two consecutive years, USRM has continued to sustain substantial revenue growth, which may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids.

USRM has been instrumental in providing more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.  

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell™, as well as veterinary stem cell training, stem cell banking, and the creation and the management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

Stem Cells Shows Promise For Repairing Torn Meniscus

SUNRISE, FL – July 10, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has demonstrated successful, in-human results in repairing meniscus tear after autologous stem cell therapy from adipose or fat tissue.  

Results are published in the scientific publication the Journal of Medical Cases, and is authored by USRM Chief Science Officer Dr. Kristin Comella and colleagues Dr. Scott Greenberg of the Magaziner Center for Wellness, and Dr. Laura Ross of Ross Orthopedic.

“The ability to provide this kind of therapy to Americans can be life changing,” said Dr. Comella.  “Use of one’s own healing cells to help repair damaged tissue rather than having to cut open or manipulate the damaged area to try to reduce pain and restore function is the most elegant form of regenerative medicine we have today.”

Meniscal injuries are the most common knee injury in the United States with an annual average of incidence of 66 per 100,000, according to a 2014 article in the Journal of Orthopedics.  Approximately 850,000 patients each year are surgically treated — often arthroscopically — for meniscal injuries.  

The paper outlines the case study of a 56-year-old male with a chronic meniscus injury.  During the 12-month follow-up period, the patient reported a reduction in pain and an improvement in knee function. Figure 1a shows a tear at baseline on the posterior horn of the medial meniscus, while Figure 1b, taken 9 months after the first injection shows complete resolution of the tear. The healed tear could not be penetrated by the probe.

The arthroscopic images showing resolution were also consistent with quality of life improvements for the patient, including a reduction in pain and resumption of normal activities. The patient experienced very little downtime and was able to resume normal activities in less than 1 week.

Dr. Comella, who has more than 20+ years’ experience, is recognized worldwide by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  USRM has been a part of more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

 

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

‘Renewing Our Heroes’ to Provide USRM Stem Cell Protocol to First Responders

SUNRISE, FL – June 5, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Renewing Our Heroes  — a charitable health initiative established to provide first responders and other civil service personnel with access to alternative medical care they would otherwise be unable to obtain — will now offer USRM stem cell procedures and protocols to its recipients following injuries and conditions that occur in the line of duty.

Established by Joseph Radich, Founder and Clinical Director of  RenewU Medical and son of an actively serving New York City firefighter, Renewing Our Heroes was created as a charitable health initiative to help individuals who voluntarily and without hesitation put their bodies, minds, families and lives on the line every day.

“I see the power of regenerative medicine, and because U.S. Stem Cell Clinic and Dr. Kristin Comella are the industry standard for holistic, autologous stem cell therapy, it only makes sense to make this protocol available to the fine men and women who serve our country,” said Radich. “Renewing Our Heroes is a way we as Americans can give back, and help them have access to what they deserve, the very best regenerative medicine has to offer.”

Dr. Kristin Comella, USRM’s Chief Science Officer, is one of the most published scientists in the world for the clinical application of autologous fat derived stem cell therapies. She is also President of the Academy of Regenerative Practices, and is a leading voice in the power of regenerative medicine.

“This is exactly why we do what we do: helping the good people of our nation find the possibility of living healthier, longer lives so that they continue to do what they do best.  For almost 20 years, I have researched, studied, tested, published and provided access to the healing, autologous stem cells in people’s bodies,” said Dr. Kristin Comella, USRM’s Chief Science Officer.  “It is a privilege to be tapping into this holistic form of stem cell therapy and to continue to serve in furthering this mission worldwide.”

“Expansion of our stem cell protocol into the line of service for our first responders means we are starting to reach more and more Americans who otherwise would never have access to this incredible regenerative therapy,” said Mike Tomas, USRM’s President and CEO.  “It is an honor for our organization to know the true heroes of our country can now have access to this standard of care.”

Dr. Comella’s leadership role inspires other organizations and physicians — 700+ clinicians and 287+ clinics worldwide — many of whom train and certify with her and the team at the U.S. Stem Cell Clinic in Sunrise, Florida.

To donate to Renewing Our Heroes, click here.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Science Officer to Present at Fifth Annual Cell Surgical World Conference

SUNRISE, FL – June 1, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, will be presenting at the Fifth Annual Cell Surgical World Conference in Beverly Hills this Saturday, June 2.

Dr. Comella is, to the Company’s best knowledge, one of the most published scientists in the clinical use of fat derived autologous stem cells.  Her work in the application of autologous (a patient’s own) stem cell therapy is unparalleled, and includes autoimmune, neurodegenerative, orthopedic and degenerative conditions.  To date, the company has worked with more than 10,000 patients and trained more than 700+ physicians worldwide.

The conference, which is hosted by the International Cell Surgical Society, features three different tracks to fit interest levels and backgrounds of all types and includes hands-on training and certification in the practice of autologous stem cell therapy. The Science Only, Physician Practicum, and Physician Practicum Plus Mini-Liposuction Certification and Training tracks provides doctors from around the world access to two days of science in lecture format; a Friday night and Saturday night social cocktail and charity dinner gala at the iconic Beverly Hilton Hotel.

To learn more about ICSS, please visit: http://internationalcellsurgicalsociety.org/

“The privilege of presenting at this conference is monumental, because it’s an opportunity to connect with regenerative-minded physicians from all over the world,” said Dr. Comella.  “I look forward to connecting with these leaders in autologous stem cell therapy and having the opportunity to share information about the remarkable results we are seeing on a regular basis.”

U.S. Stem Cell, Inc., and Dr. Kristin Comella, have taken a leadership role worldwide in the development of adipose-derived, autologous stem cell therapy.  In addition to serving as the Chief Science Officer, Dr. Comella is also President of the Academy of Regenerative Practices and is a leading voice in recognizing the power of regenerative medicine.

Along with the 700+ physicians and clinicians she has trained, she and USRM also have a presence with 287+ clinics around the world — many of which feature clinicians that are trained and certified in stem cell therapy by Dr. Comella and her team.

Autologous stem cell treatments are possible because of stem cells harvested from the patient’s own fat. Their application may offer less invasive alternatives to the use of pharmaceuticals and surgery for treating chronic pain and degeneration for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Scientist Talks Stem Cell Journey, Autologous Stem Cells with ‘Something Significant’ Happy Living Podcast

SUNRISE, FL – May 17, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, is featured in the ‘Something Significant’ Happy Living podcast with former NFL player Matt Gersper, where she discusses the inception of her work more than 19 years ago and how she and USRM’s development of novel, therapeutic adipose (fat derived) stem cell treatments, is changing lives. The interview is available for complementary playback here.

Dr. Comella, a world renowned expert in the development and clinical application of autologous stem cell products and therapies, is one voice in a growing movement recognizing the power of regenerative medicine and, in particular, autologous stem cell therapy. Last month, Dr. Comella and her team were the first in the world to publish in-human results in the scientific literature about adipose-derived, autologous stem cells for the treatment of psoriasis — a chronic, painful skin condition that affects more than 7 million Americans every year. She is frequently published in the scientific literature on the practical application of autologous stem cells for regenerative medicine.  

Matt Gersper is the founder of Happy Living and author of The Belief Road Map & Turning Inspiration Into Action.  He is a graduate of U.C. Davis and a former football player for the Canadian, USFL and NFL football leagues. During the past few years, he shifted his business to researching and sharing best practices for happy living with the world.  His mission is to inspire others to live their best self.

As more and more Americans are beginning to discover the opportunity to use their own stem cells for healing, demand for information about her work has been increasing.  Recently, she was featured in the Jeff Hays’ documentary, “The Healing Miracle (available for listen here) ;” a featured guest for the Biohacker Center in Helsinki, Finland (available in its entirety here), and a featured guest on Health Boot Camps’ “The Fountain of Health Has Been Found: An Interview with Dr. Kristin Comella,” (now available on podcast here).

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

World Bodybuilding Expert Interviews USRM Chief Science Officer At Paleo F(X) Conference

SUNRISE, FL – May 15, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the release of USRM Chief Science Officer Dr. Kristin Comella’s interview with Ben Pakulski — a world bodybuilding expert who last year received autologous stem cell therapy that successfully treated torn muscles.  Listen to the interview here, or at https://www.benpakulski.com/comella.

Dr. Comella, a world renowned expert in the development and clinical application of autologous stem cell products and therapies, is one voice in a growing movement recognizing the power of regenerative medicine and, in particular, autologous stem cell therapy. Last month, Dr. Comella and her team were the first in the world to publish in-human results in the scientific literature about adipose-derived, autologous stem cells for the treatment of psoriasis — a chronic, painful skin condition that affects more than 7 million Americans every year.

Dr. Comella is frequently published in the scientific literature on the practical application of autologous stem cells for regenerative medicine.  Her work is currently under review by the FDA, who last week announced a lawsuit against USRM’s clinic which would prevent Americans from having access to their own stem cells and would instead require them to classify their own stem cells as a drug.  USRM and its affiliates have vowed to defend the rights of its clients and the practice of regenerative stem cell therapy and its applications.

USRM’s leadership in adipose-derived, autologous stem cell therapy continues to inspire other organizations and physicians — 700+ clinicians and 287+ clinics — many of whom train and certify in stem cell therapy with Dr. Comella and her team, virtually or in person, at U.S. Stem Cell Clinic in Sunrise, Florida. She and her team continue to identify healing opportunities for the application of autologous stem cells in neurological, autoimmune, orthopedic and degenerative conditions.

Autologous stem cell treatments are possible because of stem cells harvested from the patient’s own fat. Their application may offer less invasive alternatives to the use of pharmaceuticals and surgery for treating chronic pain and degeneration for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

AdipocellTM is USRM’s proprietary, stem cell kit that enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a two-hour procedure that is generally minimally invasive and does not require general anesthesia. Using one’s own stem cells may be a significant advantage, without the potential risks of rejection or unknown exposure from donated stem cells.  

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

Autologous Stem Cell Therapy May Hold Key to Regeneration

USRM Chief Science Officer’s Live Webinar Adds Voice to Debate

SUNRISE, FL – May 14, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,  today announced the release of USRM Chief Science Officer Dr. Kristin Comella’s Stem Cell 101 Webinar from last Friday, now available for complimentary playback via live link, http://www.brainshark.com/Stemlogix/vu?pi=zGWzp5LSBz5OLvz0.

Dr. Comella, a world renowned expert in the development and clinical application of autologous stem cell products and therapies, is one voice in a growing movement recognizing the power of regenerative medicine and, in particular, autologous stem cell therapy. Last month, Dr. Comella and her team were the first in the world to publish in-human results in the scientific literature about adipose-derived, autologous stem cells for the treatment of psoriasis — a chronic, painful skin condition that affects more than 7 million Americans every year.

Dr. Comella is frequently published in the scientific literature on the practical application of autologous stem cells for regenerative medicine.  Her work is currently under review by the FDA, who last week announced a lawsuit against USRM’s clinic which would prevent Americans’ from having access to their own stem cells and would instead require them to classify their own stem cells as a drug.  USRM and its affiliates have vowed to defend the rights of its clients and the practice of regenerative stem cell therapy and its applications.

USRM’s leadership in adipose-derived, autologous stem cell therapy continues to inspire other organizations and physicians — 700+ clinicians and 287+ clinics — many of whom train and certify in stem cell therapy with Dr. Comella and her team, virtually or in person, at U.S. Stem Cell Clinic in Sunrise, Florida.

Autologous stem cell treatments are possible because of stem cells harvested from the patient’s own fat. Their application may offer less invasive alternatives to the use of pharmaceuticals and surgery for treating chronic pain and degeneration for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

AdipocellTM is USRM’s proprietary, stem cell kit that enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a two-hour procedure that is generally minimally invasive and does not require general anesthesia. Using one’s own stem cells may be a significant advantage, without the risks of rejection or unknown exposure from donated stem cells.  

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

 ###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

 

Read More

USRM Chief Science Officer, Dr. Kristin Comella, to be featured on Health Boot Camps Webinar

Sunrise, FL – May 10, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,  today announced its Chief Science Officer, Dr. Kristin Comella, is a featured guest on Health Boot Camps’ “The Fountain of Health Has Been Found: An Interview with Dr. Kristin Comella,” now available on podcast here.

“The consumer demand for sound science and information about autologous stem cell therapy is exploding,” said Dr. Comella, who is a world renowned expert with 20+ years’ experience in the development and clinical practice of stem cell products and therapies.  “It’s great to see the world waking up to how much benefit they can gain by utilizing their bodies’ own healing stem cells, and it is a privilege to help lead the way.”

Dr. Comella is extensively published in the scientific literature in the practical application of autologous stem cell therapy.  Last month, she and her team were the first in the world to publish in-human results in scientific literature of adipose stem cell therapy significantly reducing psoriasis — a condition that affects 7 million plus Americans annually.

Her leadership continues to inspire other physicians who not only refer to her published work, but also can train and certify in stem cell therapy with Dr. Comella and her team.

Autologous stem cell treatments harvested from the patient’s own fat can provide healthier alternatives to the use of pharmaceuticals for treating chronic pain and degeneration for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

AdipocellTM is a proprietary, stem cell kit that enables physicians to separate potent stem cells from a patient’s own fat tissue, which are harvested and reinserted in a minimally invasive, two-hour procedure that does not require general anesthesia. Using one’s own, autologous stem cells, may be a significant advantage since it eliminates the risks of rejection or unknown exposure from donated stem cells.  To date, more than 700+ physicians worldwide and 288 clinics have engaged with USRM to study the use autologous stem cell therapy for their own practices.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

U.S. Department of Justice Files Lawsuit at Request of FDA to Stop U.S. Stem Cell Clinic from Performing Autologous Stem Cell Procedure

USRM Will Vigorously Defend Medical Freedom of Americans

SUNRISE, FL – May 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a world leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its intention to vigorously defend a lawsuit filed today by the U.S. Department of Justice at the request of the U.S. Food and Drug Administration (FDA).  The lawsuit seeks to stop US Stem Cell Clinic and related parties from performing a surgical procedure using stem cells from autologous adipose tissue, even when a physician and patient agree that such a procedure is in the best interest of the patient. USRM believes that the patient and physician have the right to decide whether or not to use a patient’s own cells for a therapeutic purpose without federal government interference.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead, developmental product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  

#  # #  

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

 

Read More

U.S. Stem Cell Reports First Quarter Results

SUNRISE, FL – May 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced first quarter results for 2018.

Revenue increased 48%, to $1.7m from $1.15m for the first quarter of 2017.  Gross profit increased more than 52%, to $1.2m from $793k for the same period last year.  Profit margin and net cash flow from operations also increased, from 55% to 71%, and $268k to $688k, respectively.

Working capital deficit is down 11%, from $5.4m at year end 2017 to $4.8m at the end of the first quarter of this year.

For two consecutive years, USRM has sustained substantial revenue growth, which may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids.

“Our first quarter financials reflect a continued increase in market demand, as we continue to manage growth and identify ways to serve the marketplace and our business partners,” said Mike Tomas, President and Chief Executive Officer of U.S. Stem Cell, Inc.  “This is our eighth consecutive quarter of increased revenue — an indication of a possible sea change in how Americans view autologous stem cell therapy, as more and more patients seek alternatives to surgery and pharmaceuticals.”

“Our productivity continues to increase as we further our mission to help educate the public on the value of stem cell therapy, while simultaneously continuing to serve a population that is sick and tired of being sick,” said Dr. Kristin Comella, Chief Science Officer for U.S. Stem Cell, Inc.  “Helping patients repurpose their own healing cells to employ them where their bodies need them is one of the most important scientific and holistic breakthroughs we have seen in the 21st century. We continue to be dedicated to the application of this incredible therapy to help as many people as possible.”

USRM has been instrumental in administering more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.  

Dr. Kristin Comella, USRM’s Chief Science Officer, continues to enhance USRM’s visibility worldwide for autologous stem cell treatments, as well as developing and bringing USRM’s proprietary AdipocellTM kit to market.  Dr. Comella is also well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.


U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Science Officer to Host Webinar on Autologous Stem Cell Therapy

MIAMI, FL – May 8, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,  today announced its Chief Science Officer, Dr. Kristin Comella, will host a live webinar designed to inform the public about the benefits and science behind autologous stem cell therapy.

Stem Cells 101: A Patient’s Guide to Autologous Stem Cell Therapy will livestream Friday, May 11th, at twelve noon EST.  Participants who livestream the webinar may also post questions to Dr. Comella, who will answer as many livestream questions as she can during the session. “Stem Cells 101: A Patient’s Guide to Autologous Stem Cell Therapy  will also be recorded and posted following the livestream on U.S. Stem Cell’s website and in social media.

“In an era when Americans are fiercely determined to find alternatives to pain management, it’s important to understand the characteristics and science behind autologous stem cell therapy,” said Dr. Comella.  “Our goal is to inform livestreamers about key factors, such as the difference between harvesting autologous (your own) live stem cells versus utilizing a product off the shelf. Patient demand is already off the charts, but we need to provide the public with additional patient education about this emerging therapeutic and its incredible healing modality and potential, and that’s what we hope to accomplish here.”

Dr. Comella, who has more than 20+ years’ experience and is a world renowned expert in the development and clinical practice of stem cell products and therapies, is extensively published in the scientific literature in the practical application of autologous (a patient’s own) stem cell therapy.  Last month, Dr. Comella and her team were the first in the world to publish in the scientific literature in-human results of adipose stem cell therapy significantly reducing psoriasis — a condition that affects more than 7 million Americans annually. Her leadership continues to inspire other physicians who can train and certify in stem cell therapy with Dr. Comella and her team.

Autologous stem cell treatments harvested from the patient’s own fat can provide healthier alternatives to the use of pharmaceuticals for treating chronic pain and degeneration for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

AdipocellTM is USRM’s proprietary, stem cell kit that enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a two-hour procedure that is generally minimally invasive and does not require general anesthesia. Using one’s own stem cells may be a significant advantage, without the risks of rejection or unknown exposure from donated stem cells.  To date, more than 700+ physicians worldwide and 288 clinics have engaged with USRM to learn how to use autologous stem cell therapy for their own practices.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

 ###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Science Officer Featured in Live Interview for Biohacker Summit in Helsinki

MIAMI, FL – May 3, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, announced its Chief Science Officer, Dr. Kristin Comella, appeared live today as a featured guest for the Biohacker Summit blog — a component of the Biohacker Center in Helsinki, Finland.  Free online viewing of the live interview on stem cells is available in its entirety here.

Dr. Comella, who has more than 20+ years’ experience and is a world renowned expert in the development and clinical practice of stem cell products and therapies, is extensively published in the scientific literature in the practical application of autologous (a patient’s own) stem cell therapy.  Last month, Dr. Comella and her team were the first in the world to publish in the scientific literature in-human results of adipose stem cell therapy significantly reducing psoriasis — a condition that affects more than 7 million Americans annually. Her leadership continues to inspire other physicians who can train and certify in stem cell therapy with Dr. Comella and her team.

AdipocellTM is USRM’s proprietary, stem cell kit that enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in an outpatient two-hour procedure that does not require general anesthesia. Using one’s own stem cells may be a significant advantage, since rejection and other detrimental factors such as disease transmission may occur when a patient uses donated stem cells.  To date, more than 700+ physicians worldwide and 288 clinics have engaged with USRM to learn how to integrate stem cells into their own practices.

Autologous stem cell treatments harvested from the patient’s own fat can provide healthier alternatives to the use of pharmaceuticals for treating chronic pain and degeneration for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

Market Demand for Stem Cell Treatments Driving Steady Increase in USRM Sales

SUNRISE, FL – April 24, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced sales figures for 2016 and 2017 for both its AdipoCellTM proprietary stem cell kit and the stem cell banking businesses — both of which demonstrate steady growth.

From 2016 to 2017, average monthly sales of AdipoCellTM increased 11%, from 209 a month to 234 a month. Sales revenue figures for first quarter 2018 are expected to be released sometime in mid May.

“The steady and significant growth in our AdipoCellTM kits is an indicator that Americans are starting to hear about the benefits of stem cell therapy, and are taking steps to augment their health or preserve their stem cells now, so that they have reserves later in life when health or aging issues may come into play,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. “Our increase in sales reflect the growing interest in this emerging therapy. Our operations are prepared for continued growth in 2018 in order to offer this holistic therapy to as many people as possible.”

Earlier this month, USRM opened its third partially owned standalone clinic in the United States, the newest location at The Villages in North Central Florida (the two existing clinics are in Sunrise and West Palm Beach, Florida). The Company continues to identify opportunities for clinical operations worldwide.

“Our increase in patients is providing us with an opportunity to serve the needs of more and more patients who had given up hope of improving their quality of life before considering stem cell therapy as a viable option,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “We take that opportunity very seriously, and are always looking for more ways to help patients utilize their own stem cell reserves to create robust health. We look forward to identifying additional opportunities in the application of autologous stem cell therapy for neurological, autoimmune, orthopedic and degenerative conditions, and are excited about the ongoing opportunities in 2018.”

Dr. Comella, who will be speaking this week at the Paleo(X) Ancestral Healing Conference in Austin, Texas, is a world leader in stromal vascular fraction (SVF) and is a well-published trailblazer in the application of autologous stem cell therapy for a host of treatments. Since her tenure at USRM, she has performed thousands of stem cell procedures for a variety of indications.

Her experience and expertise have yielded ground-breaking results: just last month, Dr. Comella and her team were the first in the world to publish in the scientific literature in-human results of adipose stem cell therapy significantly reducing psoriasis — a condition that affects more than 7 million Americans annually. Her leadership continues to inspire other physicians who can train and certify in stem cell therapy with Dr. Comella and her team. To date, more than 700+ physicians worldwide and 288 clinics have engaged with USRM to learn how to use AdipoCellTM kits for their own practices.

AdipocellTM is a stem cell kit that enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a two-hour procedure that is generally minimally invasive and does not require general anesthesia. Using one’s own stem cells may be a significant advantage, since rejection and other detrimental factors often occur when a patient uses donated stem cells. Moreover, some of the body’s most beneficial stem cells are readily available and are stored in fat tissue, making them readily available once harvested to deploy where the body needs it most.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Announces 2017 Financial Results

SUNRISE, FL – April 16, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today filed a Form 10-K reporting year-end numbers for 2017, which reflect continued growth and increased cash flow from operations.

Revenue for 2017 increased 79% to $5.5m — up $2.4m from $3.1m in 2016.  Revenue also increased 53% in the fourth quarter of 2017 to $964k from $508k in the same quarter in 2016.  Net gross profit in 2017 increased 72% to $2.1m from $1.5m in the previous year. For the fourth quarter 2017, net gross profit was also up while overall debt decreased.

Cash flow provided from operations also increased in 2017 to $1.2m, from $112k in 2016.

USRM has sustained revenue growth for two consecutive years — from $2.2m in 2015 to $3.1m in 2016, a 41% increase; and again in 2017, with a 79% increase to $5.5m.  This sustained growth may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids. Moreover, market demand for stem cell therapy may also be increasing as a result of an improving economy, which makes out-of-pocket procedures like stem cell therapy more attainable.

“We are pleased to report our year-end results, which demonstrate we have reached a milestone in our ability to meet increasing demand for an emerging therapy in the marketplace, while simultaneously streamlining our operations,” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc.  “Marketing, finance, sales, clinical — each of our divisions is working in harmony with the other in order to attain and sustain the next level of development and growth.”

Gross profit margin decreased slightly in 2017 to 66% from 69%, due to depreciation of leased equipment.  Likewise, gross profit margin for the fourth quarter decreased from 74% to 55%, as a direct result of ramping up inventory to meet increasing demand for stem cell treatments. Increasing inventory paid off: In January 2018, USRM’s proprietary AdipoCellTM stem cell kit reached 10,000 in sales.

Operating expenses increased 36% from $3.3m in 2016 to $4.4m in 2017, primarily as a result of stock-based and other compensation.  Operating expenses also increased 14% for the fourth quarter of 2017, from $581k to $663k, primarily as a result of an increase in core operating activities.  

Loss from operations decreased 31%, or $355k, from $1.16m in 2016 to $805k in 2017. Working capital deficit is also down, 7%, from $5.8m at the end of 2016 to $5.4m at the end of 2017.  

USRM’s net loss in 2017 was $3.5m, up 68% from a net loss of $2.1m in 2016.  This increase was due to non-operating items, the largest being a $1.9m loss on change of fair value of derivative liability.  

USRM has been instrumental in performing thousands of stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.  

Dr. Kristin Comella, USRM’s Chief Science Officer, is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

Newest Clinic Opens Today at The Villages in Central Florida

SUNRISE, FL – April 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the opening its first USRM clinic in North Central Florida.

The U.S. Stem Cell Clinic of The Villages will offer alternatives to chronic pain management using USRM’s proprietary AdipoCell TM product in a minimally invasive procedure utilizing a patient’s own (autologous) stem cells. Medical director for the clinic will be Dr. Rosemary Daly, an interventional spine/pain management physician who is board certified in Anesthesiology and Pain Medicine. Dr. Daly, who graduated from the New York College of Osteopathic Medicine, is also medical director for the Regenerative Wellness Clinic (RWC) in West Palm Beach, which is also in the USRM network of stem cell treatment centers.

“Expansion of our regenerative healing centers to The Villages is an opportunity to directly serve an active community that is very proactive about seeking ways to increase their quality of life,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “We look forward to serving this vibrant community by offering holistic stem cell therapy for neurological, autoimmune, orthopedic and degenerative conditions.”

“Our vision at USRM has always been to expand access of autologous stem cell treatments to as many people as possible,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. “Now that we are seeing a steady increase in demand for stem cell therapy, which has driven our progress in reaching milestones that allow for growth, we are ready to continue expanding our network of clinics. The clinic at The Villages represents that next step.”

USRM has been instrumental in performing more than 10,000 stem cell procedures in the past 19 years for a variety of indications. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has a growing network of 288 physicians and clinics utilizing the USRM technologies, protocols and products. Dr. Comella continues to enhance USRM’s visibility worldwide for autologous stem cell treatments, as well as developing and bringing USRM’s proprietary Adipocell TM product to market: a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

Dr. Comella is also well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. Most recently, she presented a summary of peer-reviewed publications at the Academy of Regenerative Practices Conference in Weston, Florida.

U.S. Stem Cell’s novel advancements in stem cell therapy, in managements’ opinion, could be a significant alternative to the explosive opioid crisis in America — a direct results of America’s failed attempt at pain management. According to The New York Times, drug overdose is now the leading cause of death in the United States for patients under the age of 50, while the October 15, 2017, edition of 60 Minutes reports that the opioid crisis has claimed 200,000 lives in the United States over the past few decades.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry
specializing in physician training and certification and stem cell products including its lead
product Adipocell TM , as well as veterinary stem cell training and stem cell banking and creation
and management of stem cell clinics. To management’s knowledge, USRM has completed more
clinical treatments than any other stem cell company in the world.

Read More